EMA Targets Consistency In Trials For Idiopathic Pulmonary Fibrosis Drugs

 
• By Vibha Sharma
  
Doctor holding book about Idiopathic Pulmonary Fibrosis IPF.
EMA aims to unify scientific and regulatory perspectives on IPF drug development (Shutterstock)

More from Rare Diseases

More from Pink Sheet